We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+11.13%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.94B
AUM Growth
-$123M
Cap. Flow
-$193M
Cap. Flow %
-4.9%
Top 10 Hldgs %
32.83%
Holding
121
New
17
Increased
40
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
SGRY icon
Surgery Partners
SGRY
+$30.8M
2
LLY icon
Eli Lilly
LLY
+$24M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$20.7M
4
PHVS icon
Pharvaris
PHVS
+$20M
5
OSCR icon
Oscar Health
OSCR
+$18.8M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$163M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$89.3M
3
HUM icon
Humana
HUM
+$61.6M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$49.1M
5
BPMC
Blueprint Medicines
BPMC
+$32.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.7%
2 Consumer Staples 1.95%
3 Industrials 0.94%
4 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMLX icon
101
Amylyx Pharmaceuticals
AMLX
$2.59B
$2.87M 0.07%
1,011,412
+476,400
+89% +$6.23M
BMEA icon
102
Biomea Fusion
BMEA
$95M
$2.71M 0.07%
181,147
– –
NVAX icon
103
Novavax
NVAX
$1.32B
$2.57M 0.07%
537,625
– –
CYPH
104
Cypherpunk Technologies Inc
CYPH
$72.2M
$2.43M 0.06%
911,937
+79,000
+9% +$237K
SPRB
105
Spruce Biosciences
SPRB
$128M
$2.05M 0.05%
34,788
– –
VIGL
106
DELISTED
Vigil Neuroscience
VIGL
$1.61M 0.04%
471,958
– –
XLO icon
107
Xilio Therapeutics
XLO
$60.4M
$1.56M 0.04%
102,911
– –
OKUR
108
OnKure Therapeutics
OKUR
$165M
$1.25M 0.03%
75,173
– –
TLPH icon
109
Talphera
TLPH
$72.1M
$326K 0.01%
316,460
– –
NUVB.WS
110
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$40.5K ﹤0.01%
134,028
– –
AMGN icon
111
Amgen
AMGN
$224B
– –
-74,500
Closed -$21.5M
RLAY icon
112
Relay Therapeutics
RLAY
$4.37B
– –
-673,966
Closed -$7.42M
KRTX
113
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-515,024
Closed -$163M
ICVX
114
DELISTED
Icosavax, Inc. Common Stock
ICVX
– –
-868,409
Closed -$13.7M
IMGN
115
DELISTED
Immunogen Inc
IMGN
– –
-759,365
Closed -$22.5M
MRTX
116
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-835,776
Closed -$49.1M
INBX
117
CALL
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-301,400
Closed -$11.5M
1 2 3 4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Rock Springs Capital Management held 121 positions worth $3.94B, down 3% from $4.06B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rock Springs Capital Management withdrew a net $193M in Q1 2024, closing 7 positions and reducing 11 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $163M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Surgery Partners worth $29.4M.

  • Rock Springs Capital Management's largest Q1 2024 buy was Surgery Partners: 985,000 shares worth $29.4M.
  • Rock Springs Capital Management added most to Eli Lilly in Q1 2024, an estimated $24M increase.
  • Rock Springs Capital Management's biggest Q1 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $89.3M.
  • Rock Springs Capital Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $163M.
  • Rock Springs Capital Management's ten largest holdings make up 33% of its $3.94B portfolio in Q1 2024.
  • Rock Springs Capital Management opened 17 new positions and closed 7 in Q1 2024.
  • Rock Springs Capital Management's portfolio value fell 3% quarter-over-quarter to $3.94B.

Based on Rock Springs Capital Management's 13F filing for Q1 2024, filed 15 May 2024.